Moosavi, Seyed H.
Eide, Peter W.
Eilertsen, Ina A.
Brunsell, Tuva H.
Berg, Kaja C. G.
Røsok, Bård I.
Brudvik, Kristoffer W.
Bjørnbeth, Bjørn A.
Guren, Marianne G.
Nesbakken, Arild
Lothe, Ragnhild A.
Sveen, Anita http://orcid.org/0000-0001-8219-6251
Funding for this research was provided by:
Research Council of Norway (250993, 287899)
Helse Sør-Øst RHF (2017102, 2019042)
Kreftforeningen (182759-2016, 208336-2019)
Article History
Received: 14 December 2020
Accepted: 17 August 2021
First Online: 1 September 2021
Declarations
:
: All patients provided signed informed consent, and the study was conducted in accordance with the Declaration of Helsinki and approved by the Norwegian Data Protection Authority and Regional Committee for Medical and Health Research Ethics, South-Eastern Norway (REC numbers 1.2005.1629;2010/1805).
: Not applicable.
: P.W.E., A.N., R.A.L., and A.S. are co-inventors of a patent application (PCT/IB2018/000042) regarding the use of HSP90 inhibitors in relation to the consensus molecular subtypes of colorectal cancer. A disclosure of invention of the liver metastasis subtype framework (S.H.M., R.A.L., and A.S) has been reported to Inven2, a technology transfer office and limited liability company owned by Oslo University Hospital and the University of Oslo. The remaining authors declare that they have no competing interests.